Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs - CNBC
- Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs CNBC
- How big pharma is king of the hill in M&A Yahoo Finance
- The Twists and Turns in Biopharma Dealmaking: 2024 Trends Pharmaceutical Executive
- Cooley's 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024 JD Supra
- Top 10 blockbuster drugs that will become off-patent in 2024 msnNOW